CANTAZ 4.5 gm Injection

CANTAZ 4.5 gm Injection is indicated for the treatment of the following infections in adults and children over 2 years of age.

Dose alteration should only be administered as per the guidance of the Physician.

Adults and Adolescents

• Severe pneumonia including hospital-acquired and ventilator-associated pneumonia
• Complicated urinary tract infections (including pyelonephritis)
• Complicated intra-abdominal infections
• Complicated skin and soft tissue infections (including diabetic foot infections)
• Treatment of patients with bacteraemia that occurs in association with, or is suspected to be associated with, any of the infections listed above.
• Piperacillin/Tazobactam may be used in the management of neutropenic patients with fever suspected to be due to a bacterial infection.

Children 2 to 12 years of age

• Complicated intra-abdominal infections
• Piperacillin/Tazobactam may be used in the management of neutropenic children with fever suspected to be due to a bacterial infection.
• Consideration should be given to official guidance on the appropriate use of antibacterial agents.

Contraindications

• Hypersensitivity to the active substances, any other penicillin-antibacterial agent.
• History of acute severe allergic reaction to any other beta-lactam active substances (e.g. cephalosporin, monobactam or carbapenem).

Overdose

• Symptoms

There have been post-marketing reports of overdose with Piperacillin/Tazobactam. The majority of those events experienced including nausea, vomiting, and diarrhoea have also been reported with the usual recommended dose. Patients may experience neuromuscular excitability or convulsions if higher than recommended doses are given intravenously (particularly in the presence of renal failure).

• Treatment

• In the event of an overdose, Piperacillin/Tazobactam treatment should be discontinued. No specific antidote is known.
• Treatment should be supportive and symptomatic according to the patient's clinical presentation.
• Excessive serum concentrations of either piperacillin or tazobactam may be reduced by haemodialysis